AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Geert R. D'Haens  1     Brian Feagan  2     William J. Sandborn  3     Remo Panaccione  4     Julian Panés  5     Tadakazu Hisamatsu  6     Marc Ferrante  7     Ezequiel Neimark  8     Peter Bossuyt     Silvio Danese     Alexandra Song     Xiaomei Liao     Tian Feng     Rachel Duan     Sofie Berg     Jean-Frédéric Colombel     Kori Wallace    
1 Amsterdam University Medical Center,Amsterdam,Netherlands
2 Alimentiv Inc.,London,Canada
3 University of California San Diego,San Diego,United States
4 University of Calgary,Calgary,Canada
5 Hospital Clínic Barcelona,Barcelona,Spain
6 Kyorin University School of Medicine,Tokyo,Japan
7 University Hospitals Leuven,Leuven,Belgium
8 AbbVie Inc

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing